Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | HTR6 | P50406 | 8/20 | 0.61 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30592374 | 1.00 | SLC6A4 (1.00) | SLC6A4HTR6HTR2CADRB2MEN1 | |
| SCHEMBL27923059 | 0.90 | SLC6A4 (0.82) | SLC6A4HTR6HTR2CADRB2MEN1 | |
| SCHEMBL12765737 | 0.90 | SLC6A4 (0.81) | SLC6A4HTR6MEN1CYP3A4MAPT | |
| Indalpine SCHEMBL29604957 | 0.86 | SLC6A4 (1.00) | SLC6A4HTR6HTR2CADRB2CYP3A4 | |
| Indalpine SCHEMBL3863561 | 0.86 | SLC6A4 (1.00) | SLC6A4HTR6HTR2CADRB2CYP3A4 | |
| Indalpine SCHEMBL49135 | 0.86 | SLC6A4 (1.00) | SLC6A4HTR6HTR2CADRB2CYP3A4 | |
| SCHEMBL733304 | 0.85 | SLC6A4 (0.73) | SLC6A4HTR6MEN1CYP3A4MAPT | |
| Indalpine SCHEMBL141694 | 0.84 | SLC6A4 (0.97) | SLC6A4HTR6HTR2CADRB2CYP3A4 | |
| SCHEMBL4822564 | 0.83 | SLC6A4 (0.71) | SLC6A4HTR6HTR2CMEN1CYP3A4 | |
| SCHEMBL10119656 | 0.82 | SLC6A4 (0.69) | SLC6A4HTR6HTR2CADRB2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605385-B | Indole piperidine urea TRPV1 antagonism/FAAH inhibition double-target drug, preparation method and application | 河南大学 | 2023-09-08 | — | — | CN | disclosed |
| CN-114605385-A | Indolopiperidine urea TRPV1 antagonistic/FAAH inhibition double-target medicine and preparation method and application thereof | 河南大学 | 2022-06-10 | — | — | CN | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| EP-1355900-A2 | HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1073651-B1 | INDOLYL DERIVATIVES AS SEROTONERGIC AGENTS | WYETH CORP (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2002051832-A2 | HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-07-04 | — | — | WO | disclosed |
| CN-1307576-A | Serotongergic agents | AMERICAN HOME PROD (US) | 2001-08-08 | — | — | CN | disclosed |
| CN-1307573-A | Indolyl derivatives and serotonergic agents | AMERICAN HOME PROD (US) | 2001-08-08 | — | — | CN | disclosed |
| EP-1076658-A1 | SEROTONERGIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-21 | — | — | EP | disclosed |
| EP-1073651-A1 | INDOLYL DERIVATIVES AS SEROTONERGIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-07 | — | — | EP | disclosed |
| US-6066637-A | NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANT | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-23 | — | — | US | disclosed |
| WO-1999055697-A1 | SEROTONERGIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-04 | — | — | WO | disclosed |
| WO-1999055695-A1 | INDOLYL DERIVATIVES AS SEROTONERGIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-04 | — | — | WO | disclosed |
| US-5114949-A | Treating disorders associated with 5HT uptake | RHONE-POULENC SANTE (FR) | 1992-05-19 | — | — | US | disclosed |
| US-4493838-A | Medicaments containing derivatives of 3-chloro-quinoline | PHARMINDUSTRIE (FR) | 1985-01-15 | — | — | US | disclosed |
| US-4405789-A | ANTICONVULSANT, ANTIANXIETY | PHARMINDUSTRIE (FR) | 1983-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | SLC6A4 286/4885HTR6 368/4885HTR2C 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.